~~<i id='8617AA16EA'><strike id='8617AA16EA'><tt id='8617AA16EA'><pre id='8617AA16EA'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：focus 2025-08-12 00:10:21 Page View：8

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Chemotherapy shortages won’t get better under Biden’s latest plan
Next article： Activists slam private health insurers over coverage restrictions

knowledge

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Spinal cord stimulation reduces pain in amputees, study finds

LaurenGavronwalkingwithprostheticinalabattheUniversityofPittsburgh.CourtesyNathanLanger/UPMC&Pit

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

The EPA's new lead rule: How one expert crunched the numbers

RonnieLevinKayanaSzymczakfortheBostonGlobeIt’sknownthatleadinthewatersupplyhasseverehealtheffects,in